Novogenia H1 FY26 operating loss narrows 4.1% to EUR 4.7 million; revenue falls 7% to EUR 25.7 million

• Novogenia revenue fell 7% to EUR 25.7 million in H1 2026.
• Operating loss narrowed 4.1% to EUR 4.7 million, after cost cuts; prior-year operating income had been lifted by one-off other income.
• Net result swung to a loss of EUR 2.1 million, versus profit a year earlier, after a weaker financial result.
• Cash and securities totaled EUR 39.8 million at June 30, 2026.
• CEO Daniel Wallerstorfer said core genetics and personalized health products improved; the group launched MGT Plus in the U.S. and began marketing Multi-Cancer Check.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novogenia AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2405810_de) on September 28, 2026, and is solely responsible for the information contained therein.